AU6425800A - Agents for the diagnosis, prognosis and treatment of malignant diseases - Google Patents

Agents for the diagnosis, prognosis and treatment of malignant diseases

Info

Publication number
AU6425800A
AU6425800A AU64258/00A AU6425800A AU6425800A AU 6425800 A AU6425800 A AU 6425800A AU 64258/00 A AU64258/00 A AU 64258/00A AU 6425800 A AU6425800 A AU 6425800A AU 6425800 A AU6425800 A AU 6425800A
Authority
AU
Australia
Prior art keywords
prognosis
diagnosis
agents
treatment
malignant diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64258/00A
Inventor
Stephan Bergmann
Karsten Jurchott
Hans-Dieter Royer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of AU6425800A publication Critical patent/AU6425800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU64258/00A 1999-06-30 2000-06-30 Agents for the diagnosis, prognosis and treatment of malignant diseases Abandoned AU6425800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19929747 1999-06-30
DE19929747 1999-06-30
DE10015412 2000-03-23
DE10015412 2000-03-23
PCT/DE2000/002048 WO2001002556A2 (en) 1999-06-30 2000-06-30 Agents for the diagnosis, prognosis and treatment of malignant diseases

Publications (1)

Publication Number Publication Date
AU6425800A true AU6425800A (en) 2001-01-22

Family

ID=26005066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64258/00A Abandoned AU6425800A (en) 1999-06-30 2000-06-30 Agents for the diagnosis, prognosis and treatment of malignant diseases

Country Status (3)

Country Link
AU (1) AU6425800A (en)
DE (1) DE10031122A1 (en)
WO (1) WO2001002556A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10015413A1 (en) * 2000-03-23 2001-09-27 Max Delbrueck Centrum Composition for treating and diagnosing viral infections, caused by adenovirus, comprises an agent that modifies function of YB-1 protein, and YB-1 specific antibodies
AU784975B2 (en) 2000-10-11 2006-08-10 Sumitomo Chemical Company, Limited DNA-binding protein YB-1-containing collagen accumulation inhibitors
WO2002044363A1 (en) * 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
DE50112463D1 (en) * 2000-12-28 2007-06-14 Per Sonne Holm ADENOVIRAL SYSTEMS AND ITS APPLICATIONS
DE10150984A1 (en) * 2001-10-16 2003-04-17 Holm Per Sonne Expressing foreign nucleic acids with the adenoviral E2 late promoter, useful in the treatment of tumors, comprises selective activation by Y-box-binding protein-1 in tumor cell nuclei
KR101083450B1 (en) 2002-05-27 2011-11-16 페르 손네 홀름 Novel use of adenoviruses and nucleic acids coding therefor
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
DE102004060385A1 (en) * 2004-12-14 2006-07-06 Rwth Aachen Method for the determination of inflammatory processes and pharmaceutical compositions for the treatment thereof
WO2006070023A2 (en) * 2004-12-31 2006-07-06 Per Sonne Holm Method for reversing multiple resistance in animal cells
JP2009543806A (en) * 2006-07-13 2009-12-10 バーナム インスティテュート フォー メディカル リサーチ Methods and compositions for targeting gC1qR / p32
US20130019918A1 (en) 2011-07-18 2013-01-24 The Regents Of The University Of Michigan Thermoelectric devices, systems and methods
WO2014070795A1 (en) 2012-10-31 2014-05-08 Silicium Energy, Inc. Methods for forming thermoelectric elements
US9263662B2 (en) 2014-03-25 2016-02-16 Silicium Energy, Inc. Method for forming thermoelectric element using electrolytic etching
ES2868305T3 (en) 2014-03-28 2021-10-21 Univ Washington Through Its Center For Commercialization Vaccines against breast and ovarian cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016547A1 (en) * 1995-10-31 1997-05-09 The Board Of Regents, The University Of Texas System ADENOVIRUS-ANTISENSE K-ras EXPRESSION VECTORS AND THEIR APPLICATION IN CANCER THERAPY
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression

Also Published As

Publication number Publication date
DE10031122A1 (en) 2001-03-22
WO2001002556A3 (en) 2001-08-16
WO2001002556A2 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU1465801A (en) Methods for cancer prognosis and diagnosis
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU2002240336A1 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
AU2021601A (en) Composition for the treatment of dandruff
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
ZA200203166B (en) Treatment of cancer.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase